

CURRICULUM VITAE: MARC S RENDELL

ADDRESS: CREIGHTON DIABETES CENTER
CREIGHTON UNIVERSITY
SCHOOL OF MEDICINE
601 NORTH 30TH STREET
OMAHA, NEBRASKA 68131

TELEPHONE: 402-280-4319 HOME [-----]

HOSPITAL AND FACULTY APPOINTMENTS:

- | | |
|-----------|---|
| 1977-1983 | Active Staff and Assistant Professor
Division of Endocrinology
Department of Medicine
The Johns Hopkins Hospital
Baltimore, Maryland |
| 1980-1983 | Assistant Professor
Division of Nuclear Medicine
Department of Radiology
The Johns Hopkins University
School of Medicine |
| 1977-1983 | Chief, Endocrinology
Director, Radioimmunoassay Laboratory
The US Public Health Service Hospital
Baltimore, Maryland |
| 1983-1985 | Director, Diabetes Institute
City of Faith Medical and Research Center
Associate Professor, Medicine and Pathology
ORU School of Medicine |
| 1985- | Director, Creighton Diabetes Center
Associate Professor of Medicine
Associate Professor of Biomedical Sciences (1993-1995)
Professor of Medicine and Biomedical Sciences (1996-)
Creighton University School of Medicine |

EDUCATION:

- [-----] B.S. Magna Cum Laude, Honors Chemistry
CUNY, New York [-----]
- [-----] M.D., Cum Laude
SUNY Downstate Medical Center [-----]

POST DOCTORAL EDUCATION:

- [-----] Resident I, Internal Medicine
Lenox Hill Hospital, New York, N.Y.
- [-----] Research Associate
National Cancer Institute
Bethesda, Maryland
- [-----] Resident II, Internal Medicine
U. of Connecticut Medical School
Farmington, Connecticut
- [-----] Clinical Fellow
Endocrinology and Metabolism
U. of Miami Medical School
Miami, Florida

MILITARY SERVICE:

- 1973-1975 Surgeon, USPHS
Station: National Institutes of Health
Bethesda, Maryland
- 1977-1981 Senior Surgeon, USPHS
Station: Johns Hopkins Hospital
and the USPHS Hospital, Baltimore

ADMINISTRATIVE:

- 1979-1983 Member, Board of Directors
American Diabetes Association
Maryland Affiliate

1978-1981	Director, Clinical Investigations Unit USPHS Hospital, Baltimore
1980-1983	Director, Radioimmunoassay Laboratory USPHS Hospital, Baltimore
1983-1985	Director, Radioimmunoassay Section Pathology Department City of Faith Medical and Research Center
1983-1985	Director, Diabetes Institute City of Faith Medical and Research Center
1985-	Director, Creighton Diabetes Center
1986-1990	Member, Board of Directors American Diabetes Association Nebraska, Affiliate
1992-1995	Member, Research Committee American Heart Association Nebraska Affiliate
1995-1998	American Heart Association Affiliate Grant Review Study Section
1993	Member of NIH Site Visit Team: Univ. of W Virginia GCRC
1993-	Member of the HCFA Nebraska PRO Provider Quality Initiative Committee (PQIC)
2000-	Medical Director: Rose Salter Medical Research Foundation
2001-	Executive Director: Association of Diabetes Investigators

SPECIALTY CERTIFICATIONS:

[-----]	Diplomate, Internal Medicine American Board of Internal Medicine
[-----]	Diplomate, Endocrinology and Metabolism American Board of Internal Medicine
[-----]	Diplomate, Geriatric Medicine American Board of Internal Medicine
[-----]	Certified Diabetes Educator

HONORS, SCHOLARSHIPS:

- [-----] New York State Regents Scholarship
- [-----] CUNY Dr. Jonas Salk Medical Scholarship
- [-----] New York State Regents Medical Scholarship
- [--] Honors Day Winner, Downstate Medical Center

LICENSURES:

- [---] National Board of Medical Examiners
- [---] Maryland [----]
- [---] Florida ME [----]
- [---] California [-----]
- [---] Oklahoma [----]
- [---] Nevada [---]
- [---] Nebraska [---]

EDITORIAL BOARDS:

1987-1991 Board of Editors, Journal of Clinical Endocrinology and Metabolism

GRANTS:

Mathematical Modeling of Insulin Binding in the IM-9 Lymphocyte. DHEW USPHS BAL 79-46
1978-1979 \$16,000

The Dynamics of the Human Immune Response to Bovine and Pork Insulin. DHEW USPHS BAL 79-08; 1979-1981: \$5,275

Endocrinology and Diabetes Research Program, USPHS Hospital, Baltimore. DHEW USPHS BAL 80-01; 1980-1981: \$20,000

Insulin Dependence in Adult Onset Diabetes. DHEW USPHS BAL 80-53;
1980-1981: \$4,000

Endocrinology and Diabetes Research Program, USPHS Hospital, Baltimore. DHEW USPHS BAL 80-01; 1981-1982: \$24,000

The Safety, Tolerance and Efficacy of Oral Administration of AY27,773 in the Treatment of Symptomatic Diabetic, Peripheral, Sensorimeter Polyneuropathy. [-----] 81-079; 1984-1986: [-----]

The Safety, Tolerance and Efficacy of Oral Administration of AY27,773 in the Long Term Treatment of Symptomatic Diabetic, Peripheral, Sensorimeter Polyneuropathy. [-----] 81-113; 1985-1986: [-----]

Long Term One Year Open Label Safety Study of Acifran 200 mg b.i.d. in Type IIa Hyperlipidemia. [-----] 84-203; 1985-1986: [-----]

The Safety, Tolerance, and Efficacy of Oral Administration of Tolrestat (AY-27,773) in the Treatment of Moderate Non-Proliferative Diabetic Retinopathy: Effects on Retinal Morphology in Patients with Insulin Dependent and Non-Insulin Dependent Diabetes Mellitus. [-----] 81-084 and 81-085; 1985-1993: [-----]

The Safety, Tolerance, and Efficacy of Oral Administration of Tolrestat (AY-27,773) in the Prevention of Non-Proliferative Diabetic Retinopathy: Effects on Retinal Morphology and Renal Function in Patients with Insulin Dependent and Non-Insulin Dependent Diabetes Mellitus. [-----] 84-196 and 84-197; 1985-1993: [-----]

Diabetic Retinopathy and Hypertension Screening Program: [-----]. 1986-1987: [-----]

Current Perception Threshold Testing in Diabetic Neuropathy: [-----] 1987-1988: [-----]

Lovostatin Multicenter Trial: Clinical Research International ([-----]). 1987-1989: [-----]

A Phase I/II Two Week Multi-Center Double Blind, Placebo Controlled Study of the Safety, Toleration and Efficacy of CP-68,722-2 in Non-Insulin Dependent Diabetes. [-----]: 1987-1988: [-----]

The Clinical Evaluation of Patients with Type II (Non-Insulin Dependent) Diabetes Mellitus [-----], [-----]: 1988-1990: [-----]

Measurement of Current Perception Thresholds and Skin Blood Flow by Laser Doppler Flowmetry in Pentoxifylline Treated Diabetic Patients with Clinical Evidence of Sensory Diabetic Neuropathy: [-----]: 1988-1989: [-----]

A Multiclinic, Double-Blind Study to Compare the Safety and Efficacy of Lovastatin and Gemfibrozil in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): [-----]: 1988-1990: [-----]

A Multi-Center Study of the Safety of Four Different Doses of HOE843 and Placebo in Subjects with Diabetes Mellitus: [-----]: 1988-1990: [-----]

A Multicenter, Randomized, Parallel Group, Double-Masked, Placebo-Controlled Study to Determine the Effect of Daily Administration of MK-538 on the Progression of Background Retinopathy in Diabetic Patients: [-----]: [-----]: 1989-1991

An Evaluation of Pentoxifylline (Trental) in the Treatment of Symptomatic Sensory Neuropathy in Patients with Type I and Type II Diabetes Mellitus: [-----]: 1990-1991: [-----]

Laser Doppler Measurement of Skin Blood Flow in Diabetic Hypertensive Patients Treated with Isradipine and Atenolol: [-----]: 1990-1993: [-----]

Dose Response Study of HOE 490 (Glimepiride) in Subjects with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Who Have Previously Received Sulfonylurea Agents: [-----]: 1990-1991: [-----]

Cell Transit Time Analysis in Diabetes: [-----]: 1990-1991: [-----]

Randomized, Comparative Evaluation of the Efficacy and Safety of HOE 490 vs Glipizide in Patients with Non-Insulin Dependent Diabetes Mellitus: [-----]: 1992-1993: [-----]

Double Blind Randomized Comparison of Cozaar and Hyzaar vs Vasotec in Treatment of Patients with Mild to Moderate Hypertension. [-----]: 1994-1995: [-----]

Skin Blood Flow as a Peripheral Vascular Response: [-----]: 1992-1993: [-----]

A Stratified, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Cronassial in Diabetic Polyneuropathy. [-----]: 1992-1994: [-----]

A Multicenter, 12 week, Double-Blind, Placebo-Controlled, Dose Response Study of CI-991 in Patients with Non-Insulin Dependent Diabetes Mellitus. [-----]: 1993 [-----]

An Open-Label, Positive Controlled, 48 Week, Multicenter Study of Troglitazone (CI-991) in Patients with Non-Insulin Dependent diabetes Mellitus to Assess Potential Effects on Cardiac Mass and Function. [-----]: 1994-1996: [-----]

A Phase II, Multicenter, double Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) in Patients with Diabetic Peripheral Polyneuropathy. [-----]: 1995-1996: [-----]

A Randomized, Double Blind, Placebo controlled Study of the Effect of Cilostazol in Patients with Intermittent Claudication Secondary to Peripheral Vascular Disease. [-----]: 1994-1996: [-----]

A 12 week Multicenter, Double Blind, Placebo Controlled Study Assessing the Safety, tolerability and Efficacy of BRL 49653C in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM). [-----]: 1995-1996: [-----]

A Multicenter, Double Blind, Placebo Controlled Parallel Group Study of the Effects of Oral Zopolrestat in Normotensive, type I diabetes with Incipient Nephropathy (Microalbuminuria). [-----]: 1994-1996: [-----]

A Placebo Controlled, Double Blind, Randomized Three Month Maintenance Study of Repaglinide in Treatment of Patients with Type II diabetes. [-----] : 1994-1995: [-----]

Multi-Center, Double Blind, Placebo Controlled Parallel Group Comparison Study to Investigate the Efficacy and Safety of Acarbose (BAY G5421) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (Type II) Inadequately Controlled Insulin. [-----]: 1996-1997: [-----]

A Multicenter double Blind, Randomized, Parallel Group, Dose Ranging Study to Compare the Efficacy, Safety and Tolerability of Four Fixed Dose Levels of SDZ DJN 608 and Placebo in Diet-Treated Patients with Non-Insulin Dependent Diabetes Mellitus. [-----]: 1996-1997: [-----]

A Multicenter, Double blind, Randomized, combination Study to Prospectively Evaluate the Safety and Efficacy of Two Oral Fixed Doses of SDZ DJN 608 Plus Glyburide Compared to Placebo Plus Glyburide in Subjects with Non-Insulin Dependent Diabetes Mellitus. [-----]: 1996-1997: [-----]

A Phase II, Randomized, Double-Blind Placebo-Controlled, Multidose Study of the Safety and Pharmacokinetic/Pharmacodynamic Effects of RHIGF-I in Combination with Insulin for the Treatment of Type II Diabetes Mellitus. [-----]: 1996-1997: [-----]

LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) A Triple Blind Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy. [-----]: 1996-1999: [-----]

A Double-Blind, Randomized, Placebo-Controlled Parallel Group Multicenter, Flexible dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Diabetic Patients with Erectile Dysfunction. [-----]: 1996-1999: [-----]

A Double-Blind, Randomized, Placebo-Controlled Parallel Group Multicenter, Flexible dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Patients with Erectile Dysfunction. [-----]: 1996-1999: [-----]

Dose-Response Study of the Analgesic Effect of LY303870 in Patients with Diabetic Neuropathy Pain. [-----]: 1996: [-----]

A Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Trial of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (AO-128) in Type II Diabetes Mellitus Patients (Non-Insulin Dependent Diabetes Mellitus, NIDDM) Takeda Inc: 1996-1998: \$36,000

A 52-Week Open Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM). [-----]: 1996-1999: [-----]

A Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Trial of Voglibose (AO-128) 2 mg TID as Adjunctive Therapy to a Sulfonylurea Compared to a Sulfonylurea Alone in Type II Diabetes Mellitus Patients (Non-Insulin Dependent Diabetes Mellitus (NIDDM): [-----]: 1997-1998: [-----]

A 6 Month, Double-Blind, Placebo-Controlled, Multicenter Study of Troglitazone in Patients with Type II Diabetes and Congestive Heart Failure. [-----]: 1997-1999: [-----]

Effects of Prowashonupana Barley on Glycemic Response to a Test Meal in Non-Insulin Dependent Diabetes. [-----]: 1997-1998: [-----]

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multidose Study of the Combined Effects of Subcutaneously Administered Insulin and rh-IGF-I in Subjects with Insulin Dependent Diabetes Mellitus. [-----]: 1997-1998: [-----]

A Phase III, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Recombinant Human Nerve Growth Factor (RHNGF) in Subjects with Diabetic Neuropathy. [-----]: 1997-1999: [-----]

A 12-Week, Multicenter Double-Blind, Parallel, Positive-Controlled, Dose-Titration Study of Teveten (Eprosartan Mesylate, [-----]) Compared to Enalapril in Patients with Severe Systolic Hypertension. [-----]: 1997-1998: [-----]

A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of a Combination of Sulfonylurea and Two Doses of Pioglitazone (15 or 30 mg) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): [-----]: 1997-1999: [-----]

A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of a Combination of Metformin and 30 mg of Pioglitazone in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): [-----]: 1997-1999: [-----]

A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of a Combination of Insulin and Two Doses of Pioglitazone (15 or 30 mg) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): [-----]: 1997-1999: [-----]

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effects of Subcutaneous R-Methuleptin on Glycemic Control in Obese Subjects with Diet-Treated Non-Insulin Dependent Diabetes Mellitus. [-----]: 1997-1999: [-----]

A Comparison of the Efficacy, Tolerability, and cost of Amaryl Alone, Metformin Alone, or a Combination of Lower Doses of Amaryl and Metformin in Patients with Recent Onset type 2 Diabetes Mellitus (NIDDM). [-----]: 1997-1999: [-----]

A Multicenter, Open Label, Fixed Dose Extension to Study B356-E-00 to Prospectively Evaluate the Log-Term Safety and Tolerability of CDJN608 Monotherapy in Subjects with Non-Insulin Dependent Diabetes Mellitus Inadequately Controlled with Diet Alone. 1997-1998: [-----]

An 8 Week, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Ambulatory Blood Pressure Monitoring (ABPM) Comparison of Teveten (Eprosartan Mesylate [-----] 600 and 1200 mg Once Daily in Patients with Essential Hypertension. [-----]: 1996-1998: [-----]

Double Blind Efficacy and Safety Study of Two Doses of Baycol (Cerevastatin) and Pravachol (Pravastatin) in the Treatment of Patients with Primary Hypercholesterolemia. [-----]: 1998: [-----]

A Double-Blind Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide (AC137) on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type I Diabetes Mellitus. [-----]: 1998-1999: [-----]

A Double-Blind Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide (AC137) on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type II Diabetes Mellitus. [-----]: 1998-1999: [-----]

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy, Tolerability and Safety of SDZDJN 608 Monotherapy, Troglitazone Monotherapy and combination of SDZDJN 608 and Troglitazone to Placebo in Subjects with Non-Insulin Dependent Diabetes Mellitus. [-----]: 1998-1999: [-----]

Effect of Repaglinide Added to Maximal Dose Glyburide in the Treatment of Patients with NIDDM. [-----]: 1998-1999: [-----]

A 5 Week Double Blind Placebo-Controlled Trial of 3 Dosages of Pregabalin (75, 300, and 600 mg/day) for Treatment of Patients with Painful Diabetic Peripheral Neuropathy. [-----]: 1998-1999: [-----]

An Open, Non-Comparative Extension Study of Sildenafil in Patients with Erectile Dysfunction. [-----]: 1997-2001: [-----]

An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL 49553C When Administered as Monotherapy, Twice Daily, to Patients with Non-Insulin Dependent Diabetes Mellitus. [-----]: 1997-2001: [-----]

A 6-Month, Double-Blind, Placebo-Controlled, Multicenter Study of Troglitazone (CI-991) in Patients With Type 2 Diabetes and Congestive Heart Failure. [-----]: 1997-2000: [-----]

Assessment of Efficacy and Safety of Thiocetic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2a); A randomized, placebo-controlled, double-blind, multi-center long-term trial with two parallel groups. [-----]: 1997-2001: [-----]

Assessment of Efficacy and Safety of Thiocetic Acid in the Intravenous Treatment of Symptomatic Diabetic Polyneuropathy; A randomized, placebo-controlled, double-blind, multi-center trial with two parallel groups. [-----]: 1997-2001: [-----]

A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study to Evaluate the Effect of BRL 49653C 8 mg uid on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM). [-----]: 1997-2001: [-----]

An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL49563C When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus. [-----]: 1997-2001: [-----]

An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL49653 When Administered Once or Twice Daily in Combination with Insulin to Patients with Non-Insulin Dependent Diabetes Mellitus. [-----]: 1997-2001: [-----]

Pregabalin Open-Label, Extension Safety Trial in Patients With Chronic Pain. [-----]: 1997-2001: [-----]

Open-Label Long-Term Extension Study Pioglitazone in Patients With Type 2 Diabetes Mellitus. [-----]: 1998-1999: [-----]

Double-Blind Randomized Study of the Safety and Efficacy of a Combination of Metformin and 45 mg of Actos (pioglitazone HCl) Compared to a Combination of Metformin and 30 mg of Actos (pioglitazone HCl) in the Treatment of Patients with Type 2 Diabetes. [-----]: 1998-2000: [-----]

A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of Metformin Novel Oral Dose Form (Biphasic Tablet) Administered Either Once or Twice a Day in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise. [-----]: 1998-2001: [-----]

Phase II Double-Blind Randomized Placebo-Controlled 28-Day Tolerability and Preliminary Efficacy Study of Six Different Doses of VX-853 Administered to Patients with Diabetic Peripheral Neuropathy. [----]: 1998-1999: [-----]

Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 1 Diabetes Mellitus: A Six-month, Outpatient, Parallel Comparative Trial. [-----]: 1998-2000: [-----]

Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus: A Six Month, Outpatient, Parallel Comparative Trial. [-----]: 1998-2000: [-----]

Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus Not Well Controlled with Combination Oral Agents: A Three-month, Outpatient, Parallel Comparative Trial. [-----]: 1998-2000: [-----]

A 24-Week, Double-Blind Study of Troglitazone (Rezulin) in Combination With Sulfonylurea or in Combination With Sulfonylurea Plus Metformin in Type 2 Diabetes Patients Inadequately Controlled on Sulfonylurea Plus Metformin. [-----]: 1998-2001: [-----]

A Randomized, Double Blind, Placebo-Controlled, Dose Titration Study of V20001 in Type 2 Diabetic Patients Treated Only with Diet and/or Exercise. [-----]: 1999-2001: [-----]

A 26-Week Randomized, Double-Blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone (2 mg BID and 4 mg BID) Versus Placebo in Combination with Glyburide and Metformin in Patients with Type 2 Diabetes Mellitus. [-----]: 1998-2000: [-----]

A Twenty-four Week, Randomized, Double-Blind Study of the Effects of Pletal (cilostazol) versus Trental (pentoxifylline) and Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease. [----]: 1999-2000: [-----]

An Open Study of the Chronic Administration of Cilostazol (OPC-13013) in Patients with Intermittent Claudication Secondary to Chronic Occlusive Arterial Disease. [----]: 1999-2000: [-----]

Long Term Safety of Inhaled Insulin Extension of Therapy in Subjects with Type 1 or Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials. [-----]: 1999-2003: [-----]

Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naive Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated with Insulin Glargine or NPH Human Insulin. [-----]1999-2002: [-----]

A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug Naive, Recently Diagnosed Type 2 Diabetes Mellitus. [-----]: 2000: [-----]

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed Dose, Parallel Group, Three Month Comparison Study to Investigate the Efficacy and Safety of the Phosphodiesterase Type V Inhibitor BAY 38-4956 in Males with Erectile Dysfunction and With Diabetes Mellitus. [---]: 2000-2001: [-----]

A Dose Titration, Extension Study of Open-Label V20001 in Type 2 Diabetic Patients Who Have Withdrawn Prematurely from Study KD98-0603 Due to Lack of Efficacy. [-----]: 2000: [-----]

Dose Finding, Efficacy, Safety and Pharmacokinetic of AR-HO39242XX in Patients with Type 2 Diabetes. [-----]: 2001-2002: [-----]

A Multicenter, Randomized, Double-Blind Clinical Trial Comparing the Safety and Efficacy of Metformin/Glyburide Tablets to Metformin Plus Rosiglitazone Therapy in Patients with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control with Metformin Monotherapy. [-----]: 2000-2002: [-----]

Effect of Gymnema Sylvestra Added to Oral Hypoglycemic Regimens in the Treatment of Patients with NIDDM. [-----]: 2000-2001: [-----]

A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy. [-----]: 2000-2003: [-----]

The Safety and Efficacy of PNU-182716 versus Rosiglitazone: A One-year, Randomized, Double Blind, Parallel Group, Active Comparator Study. [-----]: 2000-2002: [-----]

A Prospective Randomized, Double Blind Multicenter Trial Assessing the Safety and Efficacy of Sequential (intravenous/oral) BAY 12-8039 (moxifloxacin) 400 mg Every 24 hr Compared to Intravenous Piperacillin/Tazobactam 3.0/3.75 Oral Amoxicillin/Clavulanic Acid Suspension 800 mg Every 12 hr for the Treatment of Patients with Complicated Skin and Skin Structure Infections. [---]: 2000-2004: [-----]

A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy. [-----]: 1999-2002: [-----]

Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naive Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated with Insulin Glargine or NPH Human Insulin. [-----]: 1999-2002: [-----]

Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed Dose, Parallel Group, Three Month Comparison Study to Investigate the Efficacy and Safety of the Phosphodiesterase Type V Inhibitor BAY 38-4956 in Males with Erectile Dysfunction and With Diabetes Mellitus. [---]: 2000-2001: [-----]

Dose-Finding Trial on the Anti-Diabetic Properties of Dexlipotam in Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study with Four Parallel Groups. [-----]: 2000-2003: [-----]

Efficacy, Dose-Ranging, and Safety For RWJ-241947 in Type 2 Diabetic Subjects Inadequately Controlled on Diet, Metformin, or Sulfonylurea: A 24 Week Double-Blind Randomized Placebo Controlled Study. [-----]: 2000-2001: [-----]

Dose Finding, Efficacy, Safety and Pharmacokinetic of AR-HO39242XX in Patients with Type 2 Diabetes. [-----]: 2001-2002: [-----]

A Multicenter, Randomized, Double-Blind Clinical Trial Comparing the Safety and Efficacy of Metformin/Glyburide Tablets to Metformin Plus Rosiglitazone Therapy in Patients with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control with Metformin Monotherapy. [-----]: 2000-2002: [-----]

Effect of Gymnema Sylvestra Added to Oral Hypoglycemic Regimens in the Treatment of Patients with NIDDM. [-----]: 2000-2001: [-----].

A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy. [-----]: 2000-2003: [-----]

The Safety and Efficacy of PNU-182716 versus Rosiglitazone: A One-year, Randomized, Double Blind, Parallel Group, Active Comparator Study. [-----]: 2000-2002: [-----]

Omnipatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE). [----- ---]: 2000-2001: [-----]

A Prospective Randomized, Double Blind Multicenter Trial Assessing the Safety and Efficacy of Sequential (intravenous/oral) BAY 12-8039 (moxifloxacin) 400 mg Every 24 hr Compared to Intravenous Piperacillin/Tazobactam 3.0/3.75 Oral Amoxicillin/Clavulanic Acid Suspension 800 mg Every 12 hr for the Treatment of Patients with Complicated Skin and Skin Structure Infections. [---]: 2000-2004: [-----]

A 6-week, Open-Label, Dose-comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin (ZD4522) Versus Atorvastatin, Cerivastatin, Pravastatin, and Simvastatin in Subjects with Hypercholesterolemia. [-----]: 2001-2002: [-----]

Evaluation of Diabetic Retinopathy Progression in Subjects with Type 2 Diabetes Mellitus Treated with Insulin - HOE901/4016. [-----]: 2001-2006: [-----]

Effects of Oral NO-1886 on Lipoproteins in Subjects with Type II Diabetes Mellitus who are Receiving Statin Therapy. [-----]: 2001-2003: [-----]

A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study of V20001 in Type 2 Diabetic Patients – [–]1229 US02-01. [-----]: 2002-2003: [-----]

26-week, multinational, multicenter, controlled, open 1:1 randomized, parallel clinical trial comparing HMR 1964 with regular human insulin injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH insulin, and which will lead into a comparative 26-week safety extension study (HMR 1964/3012) - HMR 1964/3002. [-----]: 2002-2003: [-----]

Double-blind Comparison of Memantine and Placebo in the Treatment of Chronic Pain in Patients with Diabetic Neuropathy - MEM-MD-06A *and* Open-label Extension of Memantine Treatment in Patients with Painful Diabetic Neuropathy - MEM-MD-06B. [-----]: 2002-2003: [-----]

12 week, multinational, multicenter, controlled, open 1:1:1 randomized, parallel clinical trial to assess noninferiority between pre- and post-meal administration of HMR 1964 and pre-meal regular human insulin in subjects with type I diabetes mellitus receiving insulin glargine as the basal insulin therapy - HMR1964A/3004. [-----]: 2002-2003: [-----]

Safety and Efficacy of Propionyl L-Carnitine in Peripheral Arterial Disease (Intermittent Claudication) as Assessed by a Fixed Treadmill Protocol in a Diabetic Population. [-----]: 2002-2004: [-----]

A multinational randomized, double-blind, placebo-controlled, force-titration, 2 X 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (IGT). [-----]: 2001-2009: [-----]

Pregabalin Open-Label Trial in Chronic Pain Patients Meeting Treatment-Refractory Patients - 1008-197. [-----]: 2001-2003: [-----]

Open-label, Randomized, Multi-center Phase IIIb, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with Type IIA and IIB Hypercholesterolemia. [-----]. 2001-2003: [-----]

26-week, multinational, multicenter, open, clinical extension trial to assess one year safety of HMR1964 compared with regular human insulin injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH insulin, and previously participating in study HMR 1964A/3002. [-----]. 2002: [-----]

PUBLICATIONS

- 1) Rendell M, Arents J: Gaussian Orbital Approximation for the Hydrogen Atom by Minimization of Variance. **J of Chem Physics** 49: 5366-5368, 1968
- 2) Rein R, Rendell MS, Harlos JP: Possible Interactions in the Primitive Translation Process. In **Molecular Orbital Studies in Chemical Pharmacology**, editor LB Kier, Springer, New York, 1970
- 3) Rendell M, Harlos J, Rein R: Specificity in the Genetic Code: The Role of Nucleotide Base-Amino Acid Interaction. **Biopolymers** 10: 2083-2094, 1971
- 4) Rendell M: A Computer Investigation into the Origin of the Code. **J of Amer Chem Soc** 94: 4337-4341, 1972
- 5) Rendell M, Soorani J: The Effect of Complex Modifiers on Large Enzyme Systems. **Mathematical Biosciences** 17: 79-88, 1973
- 6) Rendell M: Stochastic Dose-Response. **Mathematical Biosciences** 19: 307-317, 1974
- 7) Rodbell M, Lin MC, Salomon Y, Londos C, Harwood JP, Martin BR, Rendell M, Berman M: The Role of Adenine and Guanine Nucleotides in the Activity and Response of Adenylate Cyclase Systems to Hormones: Evidence for Multi-Site Transition States. **Acta Endocrinologica** 77: 11-37, 1974
- 8) Salomon Y, Lin MC, Londos C, Rendell M, Rodbell M: The Hepatic Adenylate Cyclase System I. Evidence for Transition States and Structural Requirements for Guanine Nucleotide Activation. **J of Biol Chem** 250: 4239-4245, 1975
- 9) Lin MC, Salomon Y, Rendell M, Rodbell M: The Hepatic Adenylate Cyclase System II. Substrate Binding and Utilization and the Effect of Magnesium Ion and pH. **J of Biol Chem** 250: 4246-4252, 1975
- 10) Rendell M, Salomon Y, Lin MC, Rodbell M, Berman M: The Hepatic Adenylate Cyclase System III: A Mathematical Model for the Steady State Kinetics of Catalysis and Nucleotide Regulation. **J of Biol Chem** 250: 4253-4260, 1975
- 11) Rodbell M, Lin MC, Salomon Y, Londos C, Harwood JP, Martin BR, Rendell M, Berman M: The Role of Adenine and Guanine Nucleotides in the Activity and Response

of Adenylate Cyclase Systems to Hormones. Evidence for Multi-Site Transition States. In **Advances in Cyclic Nucleotide Research**, Vol 5, edited by GI Drummond, P Greengard, A Robinson, Raven Press, New York, 1975

- 12) Rendell MS, Rodbell M, Berman M: Activation of Hepatic Adenylate Cyclase by Guanyl Nucleotides. Modeling of the Transient Kinetics Suggests an "Excited" State of GTPase Is a Control Component of the System. **J Biol Chem** 252: 7909-7912, 1977
- 13) Rendell M, McGrane D, Cuesta M: Fatal Compulsive Water Drinking. **JAMA** 240: 2557-2559, 1978
- 14) Rendell M, Slevin D, Meltz G, Simpson J, Barquet A: A Case of Maturity Onset Diabetes Mellitus Resistant to Insulin but Responsive to Tolbutamide. **Ann Int Med** 90: 195-197, 1979
- 15) Rendell M: Letter to the Editor: C-Peptide Assay. **Ann Int Med** 91: 131, 1979
- 16) Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski D, Kowarski AA: Hyperglycemia and Associated Free Insulin and Cortisol Changes in "Somogyi"-Like Patients During Continuous Glucose Monitoring. **Diabetes Care** 2: 457-464, 1979
- 17) Rendell M, Drew HM, Nickoloff E: C-Peptide as a Clinical Assay. **The Ligand Quarterly** 2: 20-23, 1979
- 18) Brown M, Salmon D, Rendell M: Clonidine Hallucinations. **Ann Int Med** 96: 1022-1036, 1980
- 19) Hamilton RG, Rendell M, Adkinson NF Jr: Serological Analysis of Human IgG and IgE Anti-Insulin Antibodies Using Solid Phase Radioimmunoassays. **J Lab Clin Med** 96: 1022-1036, 1980
- 20) Rendell M, Drew HM, Hamilton RG, Adkinson NF Jr: Exacerbation of Diabetes Mellitus by Antibodies Induced by Exogenous Insulin. **Am J Med Sci** 282: 18-26, 1981
- 21) Rendell M, Zarriello J, Drew HM, Dranbauer B, Wilson G, Waud J, Ross DA: Recovery From Decompensated Maturity Onset Diabetes Mellitus: Studies of C-Peptide Secretion. **Diabetes Care** 4: 354-359, 1981
- 22) Renie A, Hamilton RG, Adkinson NF Jr, Rendell MS: A Case of Hyperlabile Diabetes Accompanied by Insulin Resistance. **Clin Chem** 27: 1463-1464, 1981
- 23) Pincus M, DeLisi C, Rendell M: Ligand Binding to a Linear Resin Chain with Excluded Volume Effects. **Biochimica Biophysica Acta** 675: 392-396, 1981

- 24) Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A: The Dawn Phenomenon, An Early Morning Glucose Rise. Implications for Diabetic Intraday Blood Glucose Variation. **Diabetes Care** 4: 579-585, 1981
- 25) Rendell M, Ross DA, Drew HM, Zarriello J: Endogenous Insulin Secretion Measured by C-Peptide in Maturity Onset Diabetes Controllable by Diet Alone. **Arch Int Med** 141: 1617-1622, 1981
- 26) Pincus MR, Rendell M: General Quantitative Treatment for the Binding of Divalent Antibodies to Antigens Immobilized on a Solid Phase. **Proc Nat Acad Sci, USA** 78: 5924-5927, 1981
- 27) Salmon D, Rendell M, Williams J, Smith C, Ross DA, Waud J, Howard JE: Chemical Hyperthyroidism. **Arch Int Med** 142: 571-573, 1982
- 28) Meistas MT, Rendell M, Margolis ST, Kowarski AA: Estimation of the Secretion Rate of Insulin from the Urinary Excretion Rate of C-Peptide: Study in Obese and Diabetic Subjects. **Diabetes** 31: 449-453, 1982
- 29) Lassek WD, Rendell M, Ross DA, Smith C, Kernek S, Williams J, Brown M, Willingmyre L, Yamamoto L: Epidemiologic and Clinical Use of Pharmaceutical Profiles in an Ambulatory Care Data System in **Proceedings of the Sixth Annual Symposium on Computer Applications in Medical Care**, edited by BI Blum, Computer Society Press, IEEE Computer Society, Los Angeles, 1982
- 30) Rendell M, Ross DA, Lassek WD, Kernek S, Williams J, Smith C, Brown M, Willingmyre L, Yamamoto L: A Pharmaceutical Profile of Diabetic Patients. **J Chron Dis** 36: 193-202, 1983
- 31) Rendell M: Reversibility of Insulin Dependence in Diabetes. **Practical Cardiology** 9: 145-151, 1983
- 32) Rendell M: Misuse of Laboratory Tests and Diagnostic Procedures. Letter to the Editor: **New Engl J Med** 308: 1035-1036, 1983
- 33) Rendell M: The Expanding Clinical Usefulness of the C-Peptide Radioimmunoassay. **Acta Diabetol Latina** 20: 105-113, 1983
- 34) Rendell M: C-Peptide Levels as a Criterion in Treatment of Maturity Onset Diabetes. **J Clin Endo Metab** 57: 1198-1206, 1983
- 35) Rendell M: The Clinical Laboratory and Diabetes. Part I: C-Peptide. **Pathology Update Series**. Vol. I, Lesson 20, pgs 1-7, 1984

- 36) Rendell M, Kao G, Mecherikunnel P, Petersen B, Duhaney R, Nierenberg J, Rasbold K, Klenk D, Smith PK: The Use of Aminophenylboronic Acid Affinity Chromatography to Measure Glycosylated Albumin. **J Lab Clin Med** 105: 63-69, 1985
- 37) M Rendell, G Kao, P Mecherikunnel, B Petersen, R Duhaney, J Nierenberg, K Rasbold, D Klenk, PK Smith: Aminophenylboronic Acid Affinity Chromatography and Thiobarbituric Acid Colorimetry Compared for Measuring Glycated Albumin. **Clin Chem** 31: 229-234, 1985
- 38) MS Rendell: **Disorders of Glucose Metabolism. A Guide to the Use of C-Peptide and Insulin Measurements.** Monograph published and distributed by the Immunonuclear Corporation, Stillwater, Minnesota, 1984
- 39) Rasbold K, Rendell MS, Goljan E: Simple Removal of Lipids from Serum. **Clin Chem** 31:782, 1985
- 40) JL Valentine, PM Stephen, M Rendell, R Paulsen, D Shin, S Eastberg, C Smith: Noninsulin Dependent Alloxan Induced Diabetes Mellitus in the Rabbit. **Lab Animal** 4: 39-42, 1985
- 41) M Rendell, D Salmon: "Chemical Hyperthyroidism": The Significance of Elevated Serum Thyroxine Levels in L-Thyroxine Treated Individuals. **Clin Endocrinol** 22: 693-700, 1985
- 42) M Rendell, PM Stephen, R Paulsen, JL Valentine, K Rasbold, T Hestorff, S Eastberg: An Interspecies Comparison of Normal Levels of Glycohemoglobin and Glycoalbumin. **Comp Biochem & Physiol** 81B: 819-822, 1985
- 43) M Rendell, R Paulsen, S Eastberg, PM Stephen, JL Valentine, CH Smith, J Nierenberg, K Rasbold, D Klenk, PK Smith: Clinical use and time relationship of changes in glycosylated albumin and glycosylated hemoglobin measured by affinity chromatography. **Amer J Med Sci** 292: 11-14, 1986
- 44) M Rendell, K Rasbold, J Nierenberg, R Krohn, G Hermanson, D Klenk, PK Smith: Comparison and Contrast of Affinity Chromatographic Determination of Plasma Glycated Albumin and Total Glycated Plasma Protein. **Clin Biochem** 19: 216-220, 1986
- 45) M Rendell, S Dodds, LP Mercer, PM Stephen, JL Valentine, K Rasbold, J Nierenberg, PK Smith: Decreased Glycoalbumin Levels Induced by Aspirin Treatment in the Rat. **J Lab Clin Med** 108: 286-293, 1986
- 46) JJ Katims, EH Naviasky, LKY Ng, M Rendell, ML Bleeker: A New Screening Device for the Assessment of Peripheral Neuropathy. **J Occup Med** 28: 1219-1221, 1986

- 47) JJ Katims, EH Naviasky, M Rendell, ML Bleecker: Constant Current Sine Wave Transcutaneous Nerve Stimulation for the Evaluation of Peripheral Neuropathy. **Arch Phys Med Rehabil** 68: 210-213, 1987
- 48) M Rendell, C Brannan, J Nierenberg, K Rasbold, T Hestorff, D Klenk, PK Smith: Fingerstick Glycated Hemoglobin and Glycated Albumin. **Diabetes Care** 10: 629-632, 1987
- 49) ER Evans, MS Rendell, A Schueneman, F Hamilton, J Calvert: Gestational Diabetes. **Amer Fam Physician** 36(6): 119-126, 1987
- 50) MS Rendell, JJ Katims, R Richter, F Rowland: A Comparison of Nerve Conduction Velocities and Current Perception Thresholds as Correlates of Clinical Severity of Diabetic Sensory Neuropathy. **J Neurol Neurosurg Psych** 52: 502- 511, 1989
- 51) M Rendell, T Bergman, G O'Donnell, E Drobny, J Borgos, RF Bonner: Microvascular Blood Flow, Volume, and Velocity Measured by Laser Doppler Techniques in Insulin Dependent Diabetes. **Diabetes** 38: 819-824, 1989
- 52) MS Rendell, DJ Dovgan, TF Bergman, GP O'Donnell, EP Drobny, JJ Katims: Mapping Diabetic Sensory Neuropathy by Current Perception Threshold Testing. **Diabetes Care** 12: 636-640, 1989
- 53) WR Kirchain, MS Rendell: Aldose reductase inhibitors. **Pharmacotherapy** 10: 326-336, 1990
- 54) Rendell M, Fox M, Knox S, Lastovica J, Kirchain W, Meiselman HJ: The effects of glycemic control on red cell deformability determined using the cell transit time analyzer (CTTA). **J Lab Clin Med** 117: 500-504, 1991
- 55) Katims JJ, Patil AS, Rendell M, Rouvelas P, Sadler B, Weseley SA, Bleecker ML: Current perception threshold screening for carpal tunnel syndrome. **Archives of Environmental Health** 46: 207-212, 1991
- 56) Rendell MS, Giitter M, Bamisedun O, Davenport K, Schultz R: The laser Doppler analysis of posturally induced changes in skin blood flow at elevated temperatures **Clin Physiol** 12: 1-13, 1992
- 57) Rendell M, Luu T, Quinlan E, Knox S, Fox S, Kelly S, Koehler K: Red cell filterability determined using the Cell Transit Time Analyzer (CTTA): Effects of ATP depletion and changes in calcium concentration. **Biochim Biophys Acta** 1133: 293-300, 1992
- 58) Rendell M as part of the Consensus Development Group: Proceedings of a Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. **Diab Care** 15 (Suppl 3): 1080-1107, 1992

- 59) Rendell M, Bamisedun O: Skin blood flow and current perception in pentoxifylline treated diabetic neuropathy. **Angiology** 43: 843-851, 1992
- 60) Evans ER, Rendell MS, Bartek JP, Bamisedun O, Connor S, Giitter M: Current perception thresholds in aging. **Age & Ageing** 21: 273-279, 1992
- 61) Rendell M, Bamisedun O: Diabetic cutaneous microangiopathy. **Amer J Med** 93: 611-618, 1992
- 62) Evans E, Rendell M, Bartek J, Connor S, Bamisedun O, Dovgan D, Giitter M: Thermally induced cutaneous vasodilatation in aging. **J Gerontol: Med Sci** 48: M53-M57, 1993
- 63) Rendell MS, Kelly ST, Bamisedun O, Luu T, Finney DA, Knox S: The effect of increasing temperature on skin blood flow and red cell deformability. **Clin Physiol** 13: 235-245, 1993
- 64) Rendell MS, McIntyre SF, Terando JV, Kelly ST, Finney DA: Skin blood flow in the Wistar-Kyoto rat and the Spontaneously Hypertensive rat. **Comp Biochem & Physiol** 106A: 349-354, 1993
- 65) Rendell M, Kimmel DB, Bamisedun O, O'Donnell ET, Fulmer J: The health care status of the diabetic population as reflected by physician claims to a major insurer. **Arch Int Med** 153: 1360-1366, 1993
- 66) Rendell MS, Kelly ST, Finney D, Luu T, Kahler K, McIntyre SF, Ternado JV: Decreased skin blood flow early in the course of streptozotocin-induced diabetes mellitus in the rat. **Diabetologia** 36: 907-911, 1993
- 67) Rendell M, Milliken BK, McIntyre SF, Satterlee M, Eckermann AJ: The effect of aging on skin blood flow in the Wistar-Kyoto rat. **Comp Biochem Physiol A** 111A: 511-518, 1995
- 68) Rendell MS, McIntyre SF, Terando JV, Kelly ST, Finney DA, Milliken BK, Kingsley DW, Satterlee M: The effect of polycythemia on skin blood flow in hypertensive rats. **Comp Biochem Physiol A** 112A: 355-363, 1995
- 69) Rendell MS, Milliken BK, Banset EJ, Finnegan M, Stanosheck C, Terando JV: The effect of chronic hypertension on skin blood flow. **J Hypertens** 14: 609-614, 1996
- 70) Rendell M. Measurement of cutaneous perception in diabetic neuropathy. *Muscle Nerve*. 1996 Mar;19(3):406-7 :

- 71) Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J: Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. *Diabetes Care*. 1998 Dec;21(12):2056-61.
- 72) Rendell MS, Shehan MA, Kahler K, Bailey KL, Eckermann AJ: The effect of calcium channel blockade on skin blood flow in diabetic hypertension: A comparison of isradipine and atenolol. **Angiology** 48: 203-213, 1997
- 73) Rendell MS, Green SS, Catania A, Oliveto J, Wells J, Banset EJ, Wang H: Post-exercise cutaneous hyperemia resulting from local exercise of an extremity. **Clin Physiol** 17: 213-224, 1997
- 74) Rendell MS, Milliken BK, Finnegan MF, Finney DE, Healy JC: The skin blood flow response in wound healing. **Microvasc Res** 53: 222-234, 1997
- 75) Ghazzi MN, Perez, JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Rendell MS as part of the Troglitazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. **Diabetes** 46: 433-439, 1997
- 76) Rendell MS, Finnegan MF, Healy JC, Lind A, Milliken BK, Finney DE, Bonner RF: The relationship of laser Doppler skin blood flow measurements to the cutaneous microvascular anatomy. **Microvasc Res** 55: 3-13, 1998
- 77) Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG: A randomized, placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. **Diabetes Care** 21: 1897-1903, 1998
- 78) Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, Rendell M as part of NGF Study Group: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. **Neurology** 51: 695-702, 1998
- 79) Rendell M, Hovelson C, O'Connor K, Cheung L, Huard S, Kong TS, Catania A, Rosenthal R: Determination of blood flow in the finger using near infrared spectroscopy. **Clin Physiol** 18: 426 - 434, 1998
- 80) Rendell MS, Wells J: A comparison of ischemic and pressure induced hyperemia. **Arch Phys Med Rehabil** 79: 1451-1455, 1998
- 81) Rendell MS, Milliken BK, Finnegan MF, Finney DE, Healy JC, Bonner RF: The microvascular composition of the healing wound compared at skin sites with nutritive versus arteriovenous perfusion. **J Surg Res** 80: 373-379, 1998
- 82) Rendell MS, Rajfer J, Wicker P, Smith MD and the Sildenafil Diabetes Study Group: Sildenafil for treatment of erectile dysfunction in men with diabetes. A randomized controlled trial. **JAMA** 281: 421-426, 1999

- 83) Rendell MS, Finnegan MF, Pisarri T, Healy JC, Lind A, Milliken BK, Finney DE, Bonner RF: A comparison of the cutaneous microvascular properties of the Spontaneously Hypertensive rat and the Wistar Kyoto rat **Comp Biochem Physiol A** 122: 399-406, 1999
- 84) Rendell M: Book Review of Diabetic Neuropathy, 2nd ed. Dyck & Thomas, **New Engl J Med** 341: 546, 1999
- 85) Rendell MS, Milliken BK, Finnegan MF, Finney DE, Healy JC, Bonner RF: A comparison of the microvascular response in the healing wound in the spontaneously hypertensive and non-hypertensive rat. **Int J Surg Invest** 2: 17-25, 2000
- 86) Rendell M: Editorial: Dietary treatment of diabetes mellitus. **N Engl J Med** 342: 1440-1441, 2000
- 87) Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ, and the rhNGF Clinical Investigator Group: A phase III, multicenter, double-blind, placebo controlled, study of the efficacy and safety of recombinant human nerve growth factor in subjects with diabetic polyneuropathy. **JAMA** 284: 2215-2221, 2000
- 88) Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. *Clin Ther.* 2000 Dec;22(12):1395-409
- 89) Rendell MS, Kirchain WR: Drug treatments in type 2 diabetes mellitus. **Annals of Pharmacotherapy** 34: :878-95, 2000.
- 90) Raskin P, Rendell M, Riddle MC, Dole JF, Salzman A, Rosenstock J: A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin treated type diabetes. **Diabetes Care** 24: 1226-1232, 2001
- 91) Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in ;patients with type 2 diabetes mellitus: A randomized placebo-controlled study. **Am J Med** 111: 10-17, 2001
- 92) Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, Dyck PJ, Dyck PJB, Feldman EL, Fields HL, Grant IA, Griffin JW, Klein CJ, Lindblom U, Litchy WJ, Low PA, Melanson M, Mendell JR, Merren MD, O'Brien PC, Rendell M, Rizza RA, Service FJ, Thomas PK, Walk D, Wang AK, Wessel K, Windebandk AJ, Ziegler D, Zochodne DW: Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials. **J Neurol Sci** 189: 3-5, 2001

- 93) Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, Forbes WP. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. **Vasc Endovascular Surg** 36:83-91, 2002
- 94) Rendell M, Johnson ML, Smith D, Finney D, Capp C, Lammers R, Lancaster S: The Skin Blood Flow Response in the Rat Model of Wound Healing: Expression of Vasoactive Factors **J Surg Res** 107: 18-26 (2002)
- 95) Rendell M, Cariski AT, Hittel N, Zhang P: Cilostazol treatment of claudication in diabetic patients. **Curr Med Res Opin** 18: 479-487, 2002
- 96) St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. **Diabetes Care** 25: 2058-64, 2002
- 97) Rendell M, Anderson E, Schlueter W, Mailliard J, Honigs D, Rosenthal R. Determination of hemoglobin levels in the finger using near infrared spectroscopy. **Clin Lab Haematol.** 2003; 25:93-97, 2003.
- 98) Rendell M, Glazer NB, Ye Z: Combination Therapy with Pioglitazone Plus Metformin or Sulfonylurea in Patients with Type 2 Diabetes: Influence of Prior Antidiabetic Drug Regimen. **J Diab Complications** 17: 211-217, 2003.
- 99) Riddle MC, Rosenstock J, Gerich J, Rendell M as part of the Insulin /Glargine 4002 Study Investigator Group: The Treat to Target Trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. **Diab Care** 26: 3080-3086, 2003
- 100) Rendell M, Saxena S, Shah D: Cutaneous Blood Flow and Peripheral Resistance in Type II Diabetes as Compared to Intermittent Claudication **Patients Int J Angiology** 12: 166-171, 2003
- 101) McKenney JM, Jones PH, Adamczyk MA, Cain Va, Bryzinski BS, Blasetto W and Rendell M as part of the STELLAR Study Group: Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. **Current Med Res Opinions** 19: 689-696, 2003
- 102) Jones PH, Davidson MH, Stein EA and Rendell M as part of the STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin , simvastatin and pravastatin across doses (STELLAR Trial). **Am J Cardiol** 92: 152-160, 2003
- 103) Capp CL, Dorwart WC, Elias NT, Hillman SR, Lancaster SS, Nair RC, Ngo BT, Rendell MS, Smith DM: Post Pressure Hyperemia in the Rat. **Comp Biochem Physiol**

A Mol Integr Physiol. 137:533-546, 2004

- 104) Rendell M: Type 2 Diabetes Management in the Elderly **Clin Geriatrics** 12: 43-52, 2004
- 105) Bergren DR, Rendell MS: Depressed ventilatory reflexes in response to capsaicin challenge in streptozotocin treated rats. **Life Sciences** 75: 2103-2116, 2004
- 106) Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. **Drugs**. 64:1339-58, 2004.
- 107) Rendell M, Lundberg GD:. Advances In Diabetes For The Millennium: An e-Symposium. **Medscape General Medicine**. 2004;6(2). Available at: <http://www.medscape.com/viewarticle/484719>.
- 108) Rendell M: Advances in Diabetes for the Millennium: Nutritional Therapy of Type 2 Diabetes. **Medscape General Medicine**. 2004; 6(3s). Available at: <http://www.medscape.com/viewprogram/3378>.
- 109) Rendell M: Advances in Diabetes for the Millennium: Drug Therapy of Type 2 Diabetes. **Medscape General Medicine** Available at:<http://www.medscape.com/viewprogram/3410>.

PRESENTATIONS, ABSTRACTS

- 1) Rendell M: Kinetics of Hepatic Adenyl Cyclase with Imidodiphosphate Nucleotides. Presented at **Second International Conference on Cyclic AMP**, Vancouver, Canada, July, 1974
- 2) Rendell M: Kinetic Analysis of Adenylate Cyclase. Invited Speaker, **Gordon Conference on Hormone Action**, Kimball Union Academy, New Hampshire, August, 1975
- 3) Schmidt MI, Hadji-Georgopolous A, Rendell M, Margolis S, Plotnick L, Kowarski AA: Hyperglycemia and Associated Free Insulin and Cortisol Changes in "Somogyi"-Like Patients During Continuous Glucose Monitoring. **Clin Res** 27: 24A, 1979
- 4) Hamilton RG, Rendell M, Adkinson NF Jr: Quantitation of IgG Anti-Insulin Antibodies Using an ¹²⁵I-Protein A Solid Phase Radioimmunoassay. **Diabetes** 28: 433, 1979

- 5) Levine MA, Rendell M, Hsu TH, Zadik Z, Kowarski AA: Excessive Urinary Cortisol Excretion in a Euadrenal Patient. **Clin Res** 27: 574A, 1979
- 6) Rendell M, Zarriello J, Drew HM, Nickoloff E: Endogenous Insulin Secretion in Diet Controlled Maturity Onset Diabetic (MOD) Patients Previously Treated With Insulin. **Clin Res** 28: 404A, 1980
- 7) Farid RD, Greenberg F, Frank A, Caralis DG, Rendell M, Gillilan R: Non-Invasive Assessment of Left Ventricular Function in Asymptomatic Obese Maturity Onset Diabetics. **Clin Res** 28: 167A, 1980
- 8) Rendell M, Zarriello J, Drew HM, Nickoloff E: C-Peptide Secretion in Previously Ketonuric Maturity Onset Diabetic (MOD) Patients Successfully Treated by Diet Alone. **Diabetes** 29 (Suppl 2): 102A, 1980
- 9) Nickoloff E, Drew HM, Hinnenkamp M, Zarriello J, Rendell M: A Comparison of C-Peptide Secretion in Obese Versus Non-Obese Maturity Onset Diabetic (MOD) Patients Controlled by Diet Alone. **Diabetes** 29 (Suppl 2): 102A, 1980
- 10) Brown MJ, Salmon D, Rendell M: Clonidine Hallucinations. Presented at the **USPHS COA Meeting**, Houston, May, 1980
- 11) Drew HM, Nickoloff E, Rendell M: The C-Peptide Immunoassay in Serum and Urine Samples. **Ligand Quarterly** 3:45, 1980. Presented at the **Clinical Radioassay Society National Meeting**, May, 1980
- 12) Rendell M, Hamilton RG, Adkinson NF Jr, Drew HM: Exacerbation of Endogenous Insulin Deficiency by Anti-Bodies to Exogenous Insulin. **Endocrinology** 106 (Suppl 1): 269, 1980. Presented at the **Endocrine Society National Meeting**, June, 1980
- 13) Rendell M: Diabetes and Nutrition. Presented at the **26th Quarterly Fort Belvoir Family Practice Symposium**, Fort Belvoir, Va, June, 1980
- 14) Farid RD, Greenberg F, Frank A, Rendell M, Hooper J, Gillilan R: Systolic Time Interval Measurement in Asymptomatic Obese Maturity Onset Diabetics. **Clin Res** 28: 611A, 1980

- 15) Rendell MS, Zarriello J, Drew HM, Ross DA, Waud J: C-Peptide as a Measure of Insulin Secretion in Maturity Onset Diabetes-Implications for Dietary Control and Reversibility. Presented at the **Maryland Regional Meeting, American College of Physicians**, October, 1980
- 16) Rendell MS: Obesity in Maturity Onset Diabetes: Hyperinsulinemia, Insulin Resistance: What Causes It? What Can the Physician Do About It? Presented at **Recent Advances in the Management of Diabetes Mellitus**, Baltimore- Washington International Hotel, October, 1980
- 17) Rendell M, Zarriello J, Drew HM, Nickoloff E: Endogenous Insulin Secretion in Diet Controlled Maturity Onset Diabetic (MOD) Patients With and Without Normal Glucose Tolerance. **Clin Res** 28, 404A, 1980
- 18) Ross D, Rendell M, Lassek W, Yamamoto L, Williams J, Smith C, Brown M, Willingmyre L, Kernek S: The Use of Oral Hypoglycemics and Insulin Contrasted in Diabetic American Seamen and non-American Seamen Diabetic OutPatients. Presented at the **USPHS COA Meeting**, Boston, May, 1981
- 19) Ross D, Rendell M, Lassek WD, Williams J, Kernek S, Yamamoto L, Willingmyre L, Brown MJ: The USPHS ACDS Study: The Frequency of Anti-Hypertensive Drug Use Contrasted in the Diabetic and Non-Diabetic Population. **Clin Res** 29: 325A, 1981
- 20) Rendell M, Ross D, Lassek WD, Smith C, Brown MJ, Willingmyre L, Williams J, Kernek S: The USPHS ACDS Study: The Frequency of Diuretic Use Contrasted in Diabetic and Non-Diabetic Populations. **Clin Res** 29: 324A, 1981
- 21) Lassek WD, Ross D, Rendell M, Yamamoto L, Williams J, Brown MJ, Willingmyre L, Smith C, Kernek S: The USPHS ACDS Study: The Frequency of Digitalis Use Contrasted in Diabetic and Non-Diabetic Populations. **Clin Res** 29: 321A, 1981
- 22) Ross D, Lassek WD, Rendell M, Kernek S, Yamamoto L, Willingmyre L, Brown MJ, Williams J, Smith C: The USPHS ACDS Study: The Use of Anti-Anginal Agents Contrasted in Diabetic and Non-Diabetic Populations. **Clin Res** 29: 324A, 1981

- 23) Rendell M, Ross D, Lassek WD, Kernek S, Smith C, Williams J, Brown MJ, Willingmyre L, Yamamoto L: The United States Public Health Service (USPHS) Ambulatory Care Data System Study (ACDS): Prevalence of Diabetes Mellitus. **Clin Res** 29: 324A, 1981
- 24) Salmon D, Rendell M, Waud J, Williams J, Smith C, Ross D, Howard JE: Serum Triiodothyronine Values in L-Thyroxine Treated Patients with High Serum Thyroxine and Clinical Euthyroidism. **Endocrinology** 108: 340, 1981
- 25) Rendell M, Zarriello J, Drew HM, Dranbauer B, Wilson G, Waud J, Ross D: Recovery From Decompensated Maturity Onset Diabetes Mellitus: Studies of C-Peptide Secretion. **Endocrinology** 108: 344, 1981
- 26) Hamilton FA, Lundy E, Vickers S, Rendell M: The Effects of Chronic Alcoholism on Maturity Onset Diabetes Mellitus: A Retrospective Study. Presented at the **USPHS COA Meeting**, Boston, May, 1981
- 27) Rendell M, Meistas MT: Adult Onset Type I Diabetes. **Diabetes** 30 (Suppl 1) 119A, 1981
- 28) Meistas MT, Rendell M, Margolis S, Kowarski AA: Constant Rate of Urinary C-Peptide Clearance in Fasting and Post- Prandial States of Normal, Obese, and Diabetic Subjects. **Diabetes** 30 (Suppl 1) 121A, 1981
- 29) Salmon D, Rendell M, Waud J, Williams J, Smith C, Ross D, Howard JE: Serum Triiodothyronine Values in L-Thyroxine Treated Patients with High Serum Thyroxine and Clinical Euthyroidism. Presented at **Maryland American College of Physicians Regional Meeting**, Baltimore, June, 1980
- 30) Rendell M, Lassek WD, Ross DA, Smith C, Kernek S, Williams J, Brown M, Willingmyre L, Yamamoto L: The United States Public Health Service (USPHS ACDS): A Pharmaceutical Profile of Diabetic Patients. **Diabetes** 31 (Suppl 2) 409, 1982
- 31) Rendell M, Levine MA, Williams J, Zarriello J: Growth Hormone Release in Maturity Onset Diabetes. **Endocrinology** 110 (Suppl) 378, 1982

- 32) Rendell M, Lassek WD, Ross DA, Smith C, Kernek S, Williams J, Brown M, Willingmyre L, Yamamoto L: Epidemiologic and Clinical Use of Pharmaceutical Profiles in an Ambulatory Care Data System: Presented at the **Sixth Annual Symposium on Computer Applications in Medical Care**, Washington, D.C., November, 1982
- 33) Rendell M: C-Peptide Levels as a Criterion in Maturity Onset Diabetes. **Endocrinology** 112 (Suppl) 377, 1983
- 34) Rendell M, Kao G, Petersen B, Mecherikunnel P, Klenk D, Smith P: A Simple, Clinically Reliable Affinity Column Procedure for Measuring Glycoalbumin. **Diabetes** 32 (Suppl 1) 162A, 1983
- 35) Rendell M: Diagnosis and Categorization of Diabetes Mellitus. Presented at **Oklahoma State Medical Association Meeting in Association with American Diabetes Association National Program**, May, 1984
- 36) Rendell M, Valentine JL, Stephen PM, Nierenberg J, Mercer LP, Smith PK: Inhibition of Glycosylation by Acetylation. **Clin Res** 32: 851A, 1984. Presented at **AFCR Southern Society**, New Orleans, January, 1985
- 37) Rendell M, Rasbold K, Smith PK: Clinical Use of Affinity Chromatography Glycosylated Albumin Measurement. **Clin Res** 32: 851A, 1984. Presented at **AFCR Southern Society**, New Orleans, January, 1985
- 38) Rendell M, Dodds S, Mercer LP, Stephen PM, Valentine JL, Rasbold K, Nierenberg J, Smith PK. Decreased Glycoalbumin Levels Induced by Aspirin Treatment in the Rat. **Clin Res** 33: 443A, 1985
- 39) Rendell M: Management of Diabetes and Its Complications in the Elderly. Presented at the **Third Annual Chronically Ill and Aging Conference**, Oklahoma City, November, 1985
- 40) Rendell M: Is There Anything New in Diabetes. Presented at **Nebraska Chapter, American College of Physicians**, Omaha, March, 1986

- 41) Rendell M: Glycosylation: Utility as a Marker of Diabetic Control" at the **Conference Diabetic Renal Disease: Special Problems for Native Americans, sponsored by ESRD Network 10, 6th Annual Scientific Session**, Oklahoma City, April, 1986
- 42) Rendell M: New Developments in Diabetes. Presented at the **Diabetes Workshop, American Diabetes Association, Nebraska Affiliate**, Lincoln, Nebraska, April, 1986
- 43) Rendell M: Future Developments in Diabetes Treatment. Keynote Speaker at the **Annual Meeting, Minnesota Affiliate, American Diabetes Association**, Minneapolis-St Paul, October 18, 1986
- 44) Rendell M: New Developments in Diabetes. **Diabetes Workshop, Lincoln County Chapter, Nebraska ADA**, North Platte, Neb, November 1, 1986
- 45) Rendell M: Diabetes Research in the 80s: **Nebraska-Iowa Society of Medical Technologists 1987 Meeting**, Omaha, Nebraska, May 14, 1987
- 46) EP Drobny, MS Rendell, DJ Dovgan, TF Bergman, GP O'Donnell, JJ Katims: Mapping Diabetic Sensory Neuropathy by Current Perception Threshold Testing. Presented at **49th Annual Meeting, American Diabetes Association**, Detroit, Michigan, June 4, 1989
- 47) M Rendell, T Bergman, G O'Donnell, E Drobny, J Borgos, RF Bonner: Skin Microvascular Blood Flow, Volume, and Velocity Measured by Laser Doppler Techniques in Insulin Dependent Diabetes. **Diabetes** 38 (Suppl 2) 125A, 1989
- 48) Rendell M: Managing Diabetes in the 90's at the **122nd Annual Session of The Nebraska Medical Association**, Omaha, Nebraska, April 27, 1990
- 49) Rendell M, Fox M, Knox S, Lastovica J, Kirchain W, Meiselman HJ: Diabetic Red Cell Deformability Measured by Cell Transit Time Analysis (CTTA) Presented at **50th Annual Meeting, American Diabetes Association**, Atlanta, Georgia, June 17, 1990
- 50) Rendell M: Diabetes in the 21st Century at the **Annual Scientific Assembly, Louisiana Academy of Family Physicians**, Destin, Florida, July 30, 1990
- 51) Rendell M, Fox M, Knox S, Lastovica J, Kirchain W, Meiselman HJ: Diabetic Red Cell Deformability Measured by Cell Transit Time Analysis (CTTA). **Diabetes** 39 (Suppl 1):

33A, 1990

- 52) Rendell M, Bamisedun O, O'Donnell T, Fulmer J: The Health Care Impact of Diabetes Reflected by the Mutual of Omaha Database. **Diabetes** 40 (Suppl 1) 356A, 1991
- 53) Rendell M, Bamisedun O, O'Donnell T, Fulmer J: The Health Care Impact of Diabetes Reflected by the Mutual of Omaha Database. Presented at the **14th International Diabetes Federation Congress**, Washington, D.C., June 25, 1991
- 54) Rendell M: Co-Chairman of Group on Sensory Measures at the American Diabetes Association Consensus Development Conference on Standardized Measures in Diabetic Neuropathy, Washington, D.C., January 13-16, 1992
- 55) Rendell M, Bamisedun O: Diabetic cutaneous microangiopathy. *Diabetes* 1992; 41 (Suppl 1) 177A, Presented at the **52nd Annual Scientific Assembly, American Diabetes Association National Meeting**, San Antonio, Texas, June 23, 1992
- 56) Rendell M: Hypertension and Diabetes at **Topics in Primary Care for Physicians Assistants**, Omaha, Nebraska, October 3, 1992
- 57) Rendell M: Alternatives to Insulin Syringes. **Sixth Annual Diabetes Education Workshop, Bergan Mercy Medical Center**, Omaha, Nebraska, October 9, 1992
- 58) Evans E, Rendell M, Bartek J, Connor S, Bamisedun O, Dovgan D, Giitter M: Thermally induced cutaneous vasodilatation in aging. **Presented at American Geriatric Society National Meeting**, Washington, D.C., November 16, 1992
- 59) Rendell M: Isradipine in patients with hypertension and diabetes. **Presented at Teaching Consultants Conference on Hypertension**, Dallas, Texas, December 4, 1992
- 60) Rendell M: Isradipine in patients with hypertension and diabetes. **Presented at Teaching Consultants Conference on Hypertension**, Atlanta, Georgia, January 28, 1993

- 61) Rendell M, Shehan MA, Bamisedun O, Kahler K: Comparison of the effect of isradipine and atenolol on skin blood flow in diabetic hypertension. **Presented at the Eighth Annual Scientific Meeting of the American Society of Hypertension**, New York, N.Y., May 21, 1993
- 62) Rendell M, Milliken BS, McIntyre SF, Saterlee MD, Eckermann AJ: Aging of skin blood flow in the rat. Presented at the **51st Annual Scientific Meeting of the American Geriatrics Society**, Los Angeles, California, May 20, 1994
- 63) Rendell M, McIntyre SF, Terando JV, Kelly ST, Finney DA, Milliken BS, Kingsley DW III, Saterlee MD: The effect of erythropoietin on skin blood flow in the Spontaneously Hypertensive Rat as compared to the non-hypertensive Wistar-Kyoto rat. Presented at the **Ninth Annual Scientific Meeting, American Society of Hypertension**, New York, N.Y. May 12, 1994
- 64) Rendell M, Milliken BK, Lind A, Healey J: Relationship of skin blood flow to composition of the microvascular bed in spontaneously hypertensive (SHR) rats. **Amer J Hypertens** 8: 61A, 1995. Presented at the **Tenth Scientific Meeting, American Society of Hypertension**, New York, N.Y., May 18, 1995
- 65) Rendell M, Bailey K, Eckermann AJ: Skin blood flow in diabetic hypertension. **Diabetes** 44 (Suppl 1): 61A, 1995. Presented at the **55th Annual Meeting, American Diabetes Association**, Atlanta, Georgia, June 10, 1995
- 66) Rendell MS, Milliken BK, Banset EJ, Finnegan M, Stanosheck C, Terando JV: the effect of chronic hypertension on skin blood flow. Presented at the **11th Scientific Meeting, American Society of Hypertension**, New York, N.Y., May 16, 1996
- 67) Rendell MS, Finnegan MT, Pisarri T, Healy JC, Lind A, Milliken BK, Finney DE, Bonner RF. Decreased cutaneous capillary density in the Spontaneously Hypertensive Rat. Presented at the **13th Scientific Meeting, American Society of Hypertension**, New York, N.Y., May 15, 1998 **Am J Hypertens** 11: 88A, 1998

- 68) Rendell M, Moreno F: A double-blind, placebo controlled, flexible dose-escalation study assessing the efficacy and safety of sildenafil (VIAGRATM) in men with erectile dysfunction and diabetes. Presented at the **58th Annual Meeting and Scientific Sessions, American Diabetes Association**, Chicago, Illinois, June 13, 1998 Diabetes 47 (Suppl 1): A9, 1998
- 69) Rendell M, Vanderhoof J, Venn M, Shehan MA, Arndt E, Rao CS: A grain with reduced blood sugar response in diabetes. Presented at the Annual Meeting of the American Society of Clinical Nutrition, Albuquerque, New, Mexico, October 2, 1998
- 70) Rendell M, Dole J and the Rosiglitazone Study Group: Rosiglitazone improves glycemic control without adversely affecting cardiac function in type 2 diabetes. Presented at the 35th Annual Meeting of the EASD, Brussels, Belgium, October 1, 1999
- 71) Rendell M: Rosiglitazone in the management of type 2 diabetes: A U.S. physician's experience at the Interactive Advisory Meeting for United Kingdom Healthcare Practitioners. Brussels, Belgium September 30, 1999
- 72) Rendell M: Impotence in diabetes and recent approaches to treatment Presented at Diabetes Mellitus and its Complications. SUNY Buffalo, New York, October 16, 1999
- 73) Rendell M: La chimotherapie de diabetes. Lausanne, Switzerland, November 15, 1999
- 74) Rendell M: The chemotherapy of diabetes: Grand Rounds at Baptist Medical Center, Kansas City, Missouri, February 27, 2000
- 75) Rendell M: Diabetes in the elderly. Grand Rounds at Trinity Hospital, Minot, North Dakota, March 3, 2000
- 76) Rendell M: Diabetes in the elderly. At the 5th Annual Medical Conference at Medcenter One Health Systems, Bismarck, North Dakota, March 4, 2000
- 77) Rendell M: Diabetes in the elderly. At the Geriatric Symposium 2000, Avera

McKenna Hospital, Sioux City, South Dakota, March 17, 2000

- 78) Rendell M: Peripheral Arterial Disease. Grand Rounds at Research Medical Center, Kansas City, Kansas, June 21, 2000
- 79) Rendell M: Clinical Use of Rosiglitazone. At the International Conference on the Glitazones. Munich, Germany, June 30, 2000
- 80) Rendell M: Sexual Health in Diabetes. At the American Association of Diabetes Educators, San Diego, California, August 9, 2000
- 81) Rendell M: Guest Speaker Anesthetic and Life Support Drugs Advisory Committee, FDA, Gaithersburg, MD, May 16, 2002
- 82) Lancaster S, Ngo B, Dorwart W, Rendell M: Fuzzy Pressure, Presented at the Third Annual Diabetes Technology Meeting, San Francisco Airport Hyatt Hotel, November 6, 2003
- 83) Ngo B, Wiggington G, Rendell M: Skin Blood Flow in Diabetic Dermopathy, Presented at the 2004 Southern California Regional Meeting of the American College of Physicians, Los Angeles, CA